CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,048 enrolled
Drug / intervention
Guselkumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03090100
NCT03090100Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Janssen Research & Development, LLC·interventional·Posted Mar 24, 2017·Updated Oct 1, 2019

In Brief

A Phase 3 clinical trial evaluating Guselkumab, Placebo, and 1 other intervention for Psoriasis. Completed, enrolled 1,048 participants across 142 sites in 9 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Czechia, France, Germany, Hungary, Poland, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 24, 2017
Enrollment StartApr 27, 2017
Primary CompletionAug 2, 2018
Study CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.3 years ago

Interventions

Guselkumabdrug

Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.

Placebodrug

Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.

Secukinumabdrug

Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.